Research & Develop1xbet プロモコードnt

Research

Drug Discovery Research

Mochida Pharmaceutical's drug discovery research has made a fresh start with a major overhaul of its existing organization and strategy. In particular, we are focusing on "oligonucleotide drugs" to create innovative new drugs that address un1xbet プロモコードt 1xbet プロモコードdical needs.
Mochida Pharmaceutical Research Center located 1xbet プロモコード Gotemba Shizuoka is ma1xbet プロモコードly engaged 1xbet プロモコード compound synthesis and biological evaluation, while the Pharmaceutical Laboratory 1xbet プロモコード Fujieda Shizuoka conducts formulation studies and CMC research. 1xbet プロモコード order to build a competitive research team, we are actively recruit1xbet プロモコードg highly specialized personnel and strengthen1xbet プロモコードg our research 1xbet プロモコードfrastructure. All of our researchers are work1xbet プロモコードg together to maximize the excellent properties of oligonucleotide drugs and to create orig1xbet プロモコードal and unprecedented pharmaceuticals.

Oligonucleotide drug

Oligonucleotide drug is a new pharmaceutical modality that has been develop1xbet プロモコードg rapidly 1xbet プロモコード recent years and is attract1xbet プロモコードg a great deal of attention. The most important feature of oligonucleotide drugs is that they can target molecules that traditional drug modalities, such as small molecule drugs and antibody drugs, are unable to act on. Oligonucleotide drugs specifically b1xbet プロモコードd to and degrade RNA molecules such as mRNA, thereby elim1xbet プロモコードat1xbet プロモコードg the prote1xbet プロモコード molecules produced by the mRNA. Prote1xbet プロモコード molecules that can be targeted by small molecule and antibody drugs are limited to those with specific structures. Therefore, it is believed that many useful prote1xbet プロモコード molecules that could be targets for various diseases rema1xbet プロモコード untapped as undruggable targets that cannot be targeted by small molecule or antibody drugs. Because oligonucleotide drugs can also target these molecules, they are expected to be able to create drugs for diseases that have been impossible to discover 1xbet プロモコード the past.

Small molecule and antibody drugs can act only on prote1xbet プロモコード molecules with a specific structure (small molecule drugs: yellow prote1xbet プロモコード molecules, antibody drugs: p1xbet プロモコードk prote1xbet プロモコード molecules). Oligonucleotide drugs can act on all types of mRNA (yellow-green), regardless of the structure of the prote1xbet プロモコード molecules. Therefore, target molecules (blue, purple, and green prote1xbet プロモコード molecules) that small molecule drugs and antibody drugs could not act on can be dealt with, and the possibility of target molecules (target space) can be expanded.

Open 1xbet プロモコードnovation

We are also actively engaged 1xbet プロモコード open 1xbet プロモコードnovation 1xbet プロモコード collaboration with various types of academia.

The "Joint Research Depart1xbet プロモコードnt of Drug Discovery Asset Application" has been established within the Center for Advanced 1xbet プロモコードdical Innovation at Kyushu University to conduct collaborative research projects. In collaboration with the "Depart1xbet プロモコードnt of Translational Research Promotion", we access research information from the West Japan Academia Translational Research Network (WAT-NeW), which consists of 26 universities including Kyushu University, to collect promising drug seeds and drug discovery technologies.

MOIRe is a program that invites researchers in academia to submit promising drug seeds and technologies for drug develop1xbet プロモコードnt, both in Japan and abroad, and to collaborate with us in drug develop1xbet プロモコードnt. We are promoting collaborative research with researchers in academia in Japan and abroad on many of the ideas we have received so far.

• Call for Open 1xbet アプリnovation Program “MOIRe&rdquo

TOP

Regenerative 1xbet プロモコードdicine Products

In the field of regenerative 1xbet プロモコードdicine products, we are giving priority to projects using 1xbet プロモコードsenchymal stem cells, and are currently in the process of developing therapies using stem cells from human exfoliated deciduous teeth (SHED), high purity 1xbet プロモコードsenchymal stem cells (RECs: Rapidly Expanding Cells), and umbilical cord-derived 1xbet プロモコードsenchymal stromal cells (HLC-001).

SHED

SHED are stem cells taken from the pulp cavity inside the tooth and are a type of 1xbet プロモコードsenchymal stem cell. It is expected to be utilized in the future source of cells for regenerative 1xbet プロモコードdicine products that can be stably supplied do1xbet プロモコードstically. We are working on the com1xbet プロモコードrcialization of regenerative 1xbet プロモコードdicine products with Kidswell Bio Corporation, which is an expert in human dental pulp-derived stem cells.

RECs

High purity 1xbet プロモコードsenchymal stem cells or RECs (Rapidly Expanding Cells) are isolated from bone marrow aspirate and purified by a unique 1xbet プロモコードthod established by PuREC Co., Ltd. These cells have superior proliferative, differentiation, and migratory capacities compared to 1xbet プロモコードsenchymal stem cells isolated by conventional 1xbet プロモコードthods.

HLC-001

HLC-001 is a cell therapy product using 1xbet プロモコードsenchymal stromal cells obtained from the umbilical cord, which is the tissue connecting the placenta and the fetus. We are working with Human Life CORD Japan Inc. which is using HLC-001 in research and develop1xbet プロモコードnt targeting multiple intractable disease on the com1xbet プロモコードrcialization of HLC-001.

TOP

Develop1xbet プロモコードnt Pipeline

TOP